Black Diamond Therapeutics Silevertinib Phase 2 Data
Analysis based on 6 articles · First reported Apr 21, 2026 · Last updated Apr 21, 2026
The announcement of positive Phase 2 data for silevertinib by Black Diamond Therapeutics at a major oncology conference is likely to generate positive market sentiment for Black Diamond Therapeutics, potentially leading to an increase in its stock price. This event highlights the progress in developing new cancer therapies, which is generally favorable for the biotechnology and pharmaceutical industries.
Black Diamond Therapeutics announced multiple presentations at the 2026 American Society of Clinical Oncology Annual Meeting. These presentations will include oral and poster sessions detailing the safety and efficacy results of the Phase 2 study of silevertinib in treatment-naïve and previously treated patients with non-small cell lung cancer (NSCLC) with non-classical EGFR mutations. Additionally, a trial-in-progress poster will be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive glioblastoma (GBM). Initial data from the Phase 2 trial of silevertinib in frontline NSCLC patients, disclosed in December 2025, showed a 60% Objective Response Rate and 91% disease control rate. Black Diamond Therapeutics is also initiating a randomized Phase 2 trial for silevertinib in GBM patients in Q2 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard